Literature DB >> 15588223

Negative regulation of T-cell function by PD-1.

Yuan yuan Zha1, Christian Blank, Thomas F Gajewski.   

Abstract

PD-1 is a receptor inducibly expressed on CD4+ and CD8+ T cells following activation. PD-1-deficient mice develop signs of autoimmunity, suggesting a negative regulatory role for PD-1 in dampening lymphocyte responses. The expression of one ligand for PD-1, designated PD-L1 or B7-H1, on tumor cells of a variety of histologies has suggested a potential mechanism for tumor escape from immune destruction. This review summarizes data regarding PD-1 and related negative regulatory receptors, focusing on implications for potentiating antitumor immunity in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588223     DOI: 10.1615/critrevimmunol.v24.i4.10

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  29 in total

1.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

Review 2.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

3.  Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control.

Authors:  Michael Y Gerner; Lynn M Heltemes-Harris; Brian T Fife; Matthew F Mescher
Journal:  J Immunol       Date:  2013-06-26       Impact factor: 5.422

4.  Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.

Authors:  Tarsheen K Sethi; Alexandra E Kovach; Natalie S Grover; Li-Ching Huang; Laura A Lee; Samuel M Rubinstein; Yang Wang; David S Morgan; John P Greer; Steven I Park; Mary Ann Thompson-Arildsen; Ashwini Yenamandra; Cindy L Vnencak-Jones; Nishitha M Reddy
Journal:  Leuk Lymphoma       Date:  2019-06-11

5.  TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus.

Authors:  Lie Mao; Hongyan Hou; Shiji Wu; Yu Zhou; Juan Wang; Jing Yu; Xiaohui Wu; Yanfang Lu; Liyan Mao; Munyemana Jean Bosco; Feng Wang; Ziyong Sun
Journal:  Immunology       Date:  2017-02-20       Impact factor: 7.397

Review 6.  Kidney Complications of Immune Checkpoint Inhibitors: A Review.

Authors:  Roman Shingarev; Ilya G Glezerman
Journal:  Am J Kidney Dis       Date:  2019-07-11       Impact factor: 8.860

7.  Bone marrow mesenchymal stromal cells protect allograft lung transplants from acute rejection via the PD-L1/IL-17A axis.

Authors:  Naoya Ishibashi; Tatsuaki Watanabe; Masahiko Kanehira; Yui Watanabe; Yasushi Hoshikawa; Hirotsugu Notsuda; Masafumi Noda; Akira Sakurada; Shinya Ohkouchi; Takashi Kondo; Yoshinori Okada
Journal:  Surg Today       Date:  2018-03-15       Impact factor: 2.549

8.  Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.

Authors:  Seung-Pil Shin; Hye-Hyun Seo; Jae-Hun Shin; Hyung-Bae Park; Dong-Pyo Lim; Hyeon-Seok Eom; Yong-Soo Bae; In-Hoo Kim; Kyungho Choi; Sang-Jin Lee
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

9.  Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway.

Authors:  Ronald Charles; Hong-Shiue Chou; Lianfu Wang; John J Fung; Lina Lu; Shiguang Qian
Journal:  Transplantation       Date:  2013-07-15       Impact factor: 4.939

10.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

Authors:  Frank B Cortazar; Kristen A Marrone; Megan L Troxell; Kenneth M Ralto; Melanie P Hoenig; Julie R Brahmer; Dung T Le; Evan J Lipson; Ilya G Glezerman; Jedd Wolchok; Lynn D Cornell; Paul Feldman; Michael B Stokes; Sarah A Zapata; F Stephen Hodi; Patrick A Ott; Michifumi Yamashita; David E Leaf
Journal:  Kidney Int       Date:  2016-06-07       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.